37115-47-2

Usage

Uses

Used in Pharmaceutical Industry:
2-(Methylamino)acetohydrazide is used as a key intermediate for the synthesis of various bioactive compounds and pharmaceuticals. Its unique chemical structure allows for the development of novel molecules with potential therapeutic applications.
Used in Drug Discovery and Development:
2-(Methylamino)acetohydrazide is utilized as a building block in the preparation of novel molecules for drug discovery and development. Its versatile chemical properties enable the creation of new compounds with improved pharmacological properties and therapeutic potential.
It is important to handle 2-(Methylamino)acetohydrazide with care and adhere to proper safety precautions when working with this chemical to ensure the safety of researchers and the environment.

Upstream product

• 13200-60-7 Sarcosine ethyl ester 
• 5473-12-1 N-methylglycine methylester 
• 13515-93-0 N-methylglycine methyl ester hydrochloride 

Downstream Products

• 72606-31-6 C₁₄H₂₁N₃O 
• 72606-56-5 Methylamino-acetic acid [1-naphthalen-2-yl-meth-(Z)-ylidene]-hydrazide 
• 395106-20-4 ({3-[3-(4-Fluorophenyl)(1H-Indazol-5-Yl)](1H-1,2,4-Triazol-5-Yl)}Methyl)Methylamine 

Relevant academic research and scientific papers

Indazole compounds, compositions thereof and methods of treatment therewith

This invention is generally directed to the use of Indazole Compounds for treating or preventing diseases associated with protein kinases, including tyrosine kinases, such as proliferative diseases, inflammatory diseases, abnormal angiogenesis and diseases related thereto, atherosclerosis, macular degeneration, diabetes, obesity, pain and others. The methods comprise the administration to a patient in need thereof of an effective amount of an indazole compound that inhibits, modulates or regulates tyrosine kinase signal transduction. Novel indazole compounds or pharmaceutically acceptable salt thereof are presented herein.

Methods for treating an inflammatory condition or inhibiting JNK

This invention is generally directed to Indazole Derivatives having the following structure: 1 or pharmaceutically acceptable salt thereof, wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of diseases and disorders that are responsive to JNK inhibition, such as an inflammatory disease or disorder. Thus, methods of treating such diseases and disorders are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

Indazole derivatives as JNK inhibitors and compositions and methods related thereto

Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R1, R2 and A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.